Zydus Ahmedabad plant USFDA inspection closes with two observations

Zydus Lifesciences announced today that the US Food and Drug Administration (USFDA) has completed a Good Manufacturing Practice (GMP) follow-up inspection of its oncology injectable manufacturing site located near Matoda, Ahmedabad. The inspection took place from June 9th to June 18th, 2025. The inspection concluded with two observations, and Zydus specifies that none of the observations related to data integrity. The company said it will work closely with the USFDA to respond to the observations expeditiously. Zydus Lifesciences released this information in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.